C-OP04PharmatrophiX
small molecules, p75 modulation, neurotrophin receptors
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-OP04
C-OP04C-OP04small molecules, p75 modulation, neurotrophin receptors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180 patients with Alzheimer's Disease versus placebo and to access biomarker and clinical exploratory endpoints of LM11A-31-BHS
PharmatrophiX, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 14 Jun 2026 PharmatrophiX, Inc. Holding Company | 2005 | North Carolina, United States | < 10 | www.pharmatrophix.com Holding Company | 2005 | North Carolina, United States | < 10 | www.pharmatrophix.com Last update 14 Jun 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction PharmatrophiX, a biotechnology company located in San Francisco, is focused on creating dru … gh the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation Phase 2 Drug Approval 10 Jun 2024 · www.drugs.com Alzheimer's drug discovery foundation's statement on FDA advisory committee's endorsement of donanemab NEW YORK, June 10, 2024. Today, the FDA Peripheral a … gh the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. SOURCE Alzheimer's Drug Discovery Foundation Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox. Phase 2 Drug Approval 17 May 2024 · www.prnewswire.com New Study in Nature Medicine Shows Novel Neuroprotective Drug Candidate Meets Primary E … rofessor of Medicine and Neurology at Stanford University, and inaugural Goodes Prize honoree. "Without ADDF funding, LM11A-31 would not have reached this milestone. My 25-year-long relationship with the foundation began when this molecule was first discovered in the lab and has catalyzed this drug through basic mechanism and preclinical studies to the clinical phase, showing the importance of advancing translational research that will pave the way for new treatments and prev … gh the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation Phase 2 100 Deals associated with PharmatrophiX, Inc. Login to view more data 100 Tra
PharmatrophiX | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Confer … will be supported by private funding already raised by PTX and the goal of this application is to obtain ADDF support for the final key support that will make this trial possible. View all funding to this organization (6) View all funding to this investigator (8) GET IN TOUCH [email protected] 212.901.8000 Alzheimer's Drug Discovery Foundation A GuideStar-Rated Charity 57 West 57th Street, Suite 904 New York, NY 10019 [email protected] 212.901.8000 © Copyright … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
David Setboun, Pharm.D., MBA - Email & Phone Number | PharmatrophiX, Inc. Log In loading... Find Any Email, Find Any Phone Number Find by Name Find by Company Find from LinkedIn Find Contact Try with: Jensen Huang @ nvidia.com Click to autofill What LeadContact does well Find anyone's verified emails, phone numbers and decision makers with 98% accuracy. Sign Up for Free Find Emails Access verified, up-to-date emails — instantly. 120M+ emails found for users Find Phone Numbers Cross-validated phone data from multiple top sources. 60M+ phones delivered Find Decision Makers Quickly find
What a transformative week at Fierce Biotech. I was honored to present PharmatrophiX, Inc.’s research and approach to Alzheimer’s treatment, and further to connect with inspiring colleagues driving… | David Setboun, Pharm.D., MBA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update y
Anne Chun Longo - CEO at PharmatrophiX | The Org Platform Enrich Pricing Log in Sign up PharmatrophiX Anne Chun Longo Unverified Anne Chun Longo CEO Contact Anne Longo has been CEO of PharmatrophiX since 2010 and also serves as the Senior Director of Development for Neurology & Neurological Sciences at Stanford University. Following her graduation from Stanford University, she led programs at the NIH and at the Alliance for Aging Research in Washington DC. Ms. Longo also served in business development at Age Wave and at Charles Schwab in San Francisco. As CEO of PharmatrophiX, Ms. Longo
EX-99.1 2 d292116dex991.htm ANNUAL REPORT OF ELAN CORPORATION, PLC Annual Report of Elan Corporation, plc Table of Contents Exhibit 99.1 2011 ANNUAL REPORT Table of Contents ABOUT US Elan, an Irish public company, has a long history as a pioneer in treating neurodegenerative disease. We have generated the core science and fundamental discoveries responsible for breakthrough compounds that profoundly impact multiple sclerosis and Crohn’s disease and that may have an impact on Alzheimer’s disease. Parkinson’s disease and the optimisation of our science across a broad … disease, increased our focus on Parkinson’s disease and also extended the application of proven science to other disease areas. We have made significant progress in a number of programmes both internally and with our collaborators. 2012 will be an important year in this regard. The continuing success of Tysabri is highlighted by the 23% growth in in-market sales and 13% growth in patients on therapy in 2011. The sale of our Elan Drug Technologies (EDT) business to Alker … disease, increased our focus on Parkinson’s disease and also extended the application of proven science to other disease areas. Table of Contents 6 Elan Corporation, plc 2011 Annual Report CEO REVIEW Dear Shareholders, 2011 was a transformational year for Elan: we completed the planned separation of our highly successful Elan Drug Technologies (EDT) business thereby advancing a number of long-standing strategic and financial objectives; for Tysabri, we rec … dosis, diabetes, cancer and macular degeneration. Neotope’s strategy is to apply its expertise in generating novel therapeutic antibodies working with a broad range of collaborators in specific disease models, to select candidates for further clinical development. Approach An epitope is the molecular target recognised by an antibody. A neo-epitope is formed upon a modification of a protein. Of particular interest are sites on proteins that become accessible only after mo … Onclave) was formed to develop assets originating from Elan that have potential application in oncology related diseases. Onclave’s lead programme, NEOD001, which originated from Neotope, is being investigated for the potential treatment of AL amyloidosis, a fatal disease involving abnormal accumulation of amyloid in organs and tissue. In 20
Entropy Neurodynamics' TRP-8802 IBS Breakthrough | Entropy Neurodynamics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
Alzheimer’s Drug Featured in Time Was Made Possible by the ADDF | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting Fo … overy Foundation (ADDF) grantee and recipient of our inaugural Melvin R. Goodes Prize in 2015. Dr. Longo is a professor and chairman of the Department of Neurology and Neurological Sciences at Stanford University School of Medicine and founder and chairman of biopharmaceutical firm PharmatrophiX. His drug, LM11A-31, targets the p75 receptor on the surface of neurons. Dr. Longo explains that in targeting this receptor, the drug “counteracts much of the abnormal signaling … ry step of the way, with seven grants totaling over $2 million. The most recent grant—$500,000 awarded in late 2015—is supporting the phase 2a clinical trial of LM11A-31 to test its effectiveness in patients with Alzheimer’s. Upon winning the Goodes Prize last year, Dr. Longo said: “Our approach was a highly risky one, with no good precedent in the field of neuroscience. Our success in obtaining NIH funding for this work required that we first demonstr … f patients in just a few years." Tags: amyvid™ clinical trials melvin r. goodes prize neuroprotection pharmatrophix Category: Developing Drugs February 25, 2016 Related Content Dr. Frank Longo Wins Inaugural Melvin R. Goodes Prize announcements Closing in on a Cure: Dr. Frank Longo and C-31 blog Don’t miss any updates about our work— Get our newsletter! Alzheimer's Drug Discovery Foundation A GuideStar-Rated Charity 57 West 57th Street, Suite 904 New York, NY 10019 info@alzdi … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention
ALZHEIMER'S DRUG DISCOVERY FOUNDATION'S (ADDF) STATEMENT ON FDA ADVISORY COMMITTEE'S ENDORSEMENT OF DONANEMAB Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Mult … gh the generosity of its donors, the ADDF has awarded more than $290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries. To learn more, please visit: http://www.alzdiscovery.org/ . SOURCE Alzheimer's Drug Discovery Foundation 21 % more press release views with Request a Demo × Modal title Also from this source New Alzheimer's & Dementia Paper Highlights SpeechDx's Role in Advancing AI-Driven Tools for … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Dr. Frank Longo Wins Alzheimer's Drug Discovery Foundation's Inaugural Melvin R. Goodes Prize for Researchers Working in Alzheimer's Drug Discovery Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Release … k Longo Wins Alzheimer's Drug Discovery Foundation's Inaugural Melvin R. Goodes Prize for Researchers Working in Alzheimer's Drug Discovery Dr. Longo's Pioneering Approach May Soon Lead to New Disease Modifying Drugs News provided by Alzheimer's Drug Discovery Foundation Sep 16, 2015, 12:46 ET Share this article Share to X Share this article Share to X NEW YORK , Sept. 16, 2015 /PRNewswire-USNewswire/ -- Physician-scientist Frank M. Longo , MD, PhD, has been named the inaugur … l winner of the Alzheimer's Drug Discovery Foundation's (ADDF) Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery, the first prize to specifically recognize researchers working in novel and promising areas of Alzheimer's drug discovery. Dr. Longo is Professor and Chairman of the Department of Neurology and Neurological Sciences at Stanford University School of Medicine and founder and Chairman of biopharmaceutical firm PharmatrophiX. Continue Reading Frank M. … hD "It is fitting that Dr. Longo is the recipient of the first Melvin R. Goodes Prize, as his pioneering research has significant potential to result in successful disease-modifying treatments for Alzheimer's within the next few years," said Howard Fillit , MD, Founding Executive Director and Chief Scientific Officer of the ADDF. "By establishing this prize, we seek to celebrate the research of scientists such as Dr. Longo, whose drug discovery work often goes unrecognized, a … e drug discovery work often goes unrecognized, and provide them with a monetary award, so that they can continue taking bold chances in pursuit of novel and effective treatments." Dr. Longo and colleagues developed an innovative approach to identifying and developing small, orally available drugs that mimic the function of normal brain proteins (
Meet the Faculty | AD/PD™ 2025 Search for: About Welcome Message IMPORTANT DELEGATE INFORMATION Your Guide to AD/PD™ 2025 AD/PD™ Committee Past Conferences AD/PD™ 2024 Photo Gallery Partners & Related Events AD/PD™ Education FAQ Contact Us Resources Virtual Platform Login Download the AD/PD™ 2025 App #ADPD2025 Photo Contest Discover Vienna Program Scientific Program Meet the Faculty Hear From Our Speakers Plenary Speakers Speaker Lecture Titles Forum Discussions Meet the Professor Lunch Sessions CME-CPD Information Abstracts Abstract Submission Abstract Topics AD/PD™ 2025 Junior Faculty Aw
%PDF-1.7 %���� 556 0 obj > endobj 584 0 obj >/Filter/FlateDecode/ID[ ]/Index[556 82]/Info 555 0 R/Length 130/Prev 349847/Root 557 0 R/Size 638/Type/XRef/W[1 2 1]>>stream h�bbd``b`�L@��H0� �� �|!$�g � HL Hpā�6�� �A��@��H�傔� �" �wH��2'A܋ %r �Az+���&F�= g�\3� �44�?��;�Ë endstream endobj startxref 0 %%EOF 637 0 obj >stream h�b```� � �@(������� ̏�{z�X�1��u�^����V6�� ��V|- 0m,M�}�����a9"t��)��%� > endobj 558 0 obj > endobj 559 0 obj >/Font >/ProcSet[/PDF/Text]/XObject >>>/Rotate 0/StructParents 0/TrimBox[0 0 595.276 799.37]/Type/Page>> endobj 560 0 obj >stream … _��;����ڐocB���p���w��7 ��.H�^Zh ��@?�t�!Y�Q�Y��%�j>(iBӁ���m� h, >stream application/postscript master_template_NEW Bella6 Adobe Illustrator 26.4 (Macintosh) 2023-12-13T17:09:27Z 2023-12-13T17:09:27Z 2023-12-13T17:09:27Z xmp.did:a074ed56-d651-4bd8-ad47-c14cb3ca645f xmp.iid:a074ed56-d651-4bd8-ad47-c14cb3ca645f uuid:AD83186F157FE111B718E1DB816FAC55 proof:pdf xmp.iid:2b647d6a-edc9-4488-aa96-cea0a35fc686 xmp.did:8a72205b-b318-4291-b4d3-c0964eafbeaa uuid:AD83186F157FE111B71 … 4d3-c0964eafbeaa uuid:AD83186F157FE111B718E1DB816FAC55 proof:pdf converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:F87F1174072068118C1490BD3450264E 2012-04-23T11:19:36+01:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from app … t to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.ill … from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:05801174072068118A6DA55D7C3CC575 2012-07-11T
PharmatrophiX - HQ | The Org Platform Enrich Pricing Log in Sign up PharmatrophiX Offices HQ Unverified HQ 0 people · 0 jobs PharmatrophiX's headquarters in Raleigh, NC, United States Office location People ( 0 ) No people in this office Jobs ( 0 ) No jobs in this office Other offices View all offices No other offices Company About Contact Blog Business Solutions Trust Pricing Directory Companies People Features Employer Branding Professional Networking Job Discovery Social © 2026 Orgio, Inc. Terms Privacy Do not sell my info
Runners For Alzheimer's Research | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports … therapeutics lewy body dementia ltd. m3 biotechnology medicare melvin r. goodes prize memories matter mild cognitive impairment misfolded proteins mitochondria & metabolic function mri multiple scleroris neuroimaging neurolucent neuroprotection neurotherapia neurotransmitters new staff new trustees nyc marathon oryzon genomics partnership pet scan pharmatrophix policy prevention prion disease proteostasis psychogenics repurposing rexceptor rodin therapeutics runners for alzhe … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
Longo Lab Members | Longo Lab | Stanford Medicine Skip to Content Stanford Medicine Longo Lab – Neurology & Neurological Sciences Site Nav Menu Longo Lab Stanford Medicine Explore Stanford Medicine Health Care Find a doctor Adult-care doctor Pediatrician or pediatric specialist Obstetrician Clinics & Services Adult care Pediatric care Obstetrics Clinical trials Locations Stanford Health Care Stanford Children's Health Emergency Department Dial 911 in the event of a medical emergency Explore Health Care Learn how we are healing patients through science & compassion Back Research B … h fellows Research News Neuroscientist Michelle Monje awarded MacArthur 'genius grant' Explore Research Learn how we are fueling innovation Back Education MD program PA Programs PhD programs Masters programs Continuing Medical Education Postdoctoral scholars Residencies & fellowships High School & Undergraduate Programs See all Education Resources Academic profiles School Administration Basic science departments Clinical science departments Alumni services Faculty res … rained as a resident in neurology at UC San Francisco where he also completed a fellowship in neurobiology. He joined the UCSF faculty and eventually served as Professor and Vice Chair of UCSF’s Department of Neurology. Before joining Stanford in 2006, Dr. Longo was the H. Houston Merritt Professor and Chair of Neurology at the University of North Carolina–Chapel Hill. At Stanford, he served as the Chair of the Department of Neurology and Neurological Sciences from 2006 to 20 … h mechanisms. Dr. Longo is the 2015 recipient of the inaugural Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery from the Alzheimer’s Drug Discovery Foundation, and he currently serves on the National Advisory Council on Aging for the NIH. He is Founder and Board Chair for PharmatrophiX, a clinical-stage company focused on small molecule therapeutics for neurodegenerative diseases. Instructors Amira Latif-Hernandez, PhD Instructor, Neurology and Neurological … tau seeds to cognitive decline. During this time, she was awarded a NIH F99/K00 fellowship from the National Institute on Aging to support her transition to postdoctoral training at Stanford University. In the Longo Lab, she is interested in identifying conserved proteomic biomarkers of neurotrophin receptor ligand treatment across mouse models a
New Staff | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Conference … therapeutics lewy body dementia ltd. m3 biotechnology medicare melvin r. goodes prize memories matter mild cognitive impairment misfolded proteins mitochondria & metabolic function mri multiple scleroris neuroimaging neurolucent neuroprotection neurotherapia neurotransmitters new staff new trustees nyc marathon oryzon genomics partnership pet scan pharmatrophix policy prevention prion disease proteostasis psychogenics repurposing rexceptor rodin therapeutics runners for alzhe … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
CiminoCare Staff Attend 19th Annual Updates on Dementia Conference - CiminoCare Resize Fonts A Decrease font size. A Reset font size. A Increase font size. Care Philosophy Our Philosophy The CiminoCare Story Care Services Overview Assisted Living Memory Care Independent Living Additional Services Care Communities All Our Communities Burlingame Villa Citrus Heights Terrace Country Club Manor Courtyard Terrace Eagle Lake Village Grand River Villa Mills Estate Villa River Fountains of Lodi Sunshine Assisted Living Walnut House WestHaven – Assisted Living WestHaven – Memory Care Neighb … llion Americans with dementia who live alone . The conference also featured the award-winning researcher and clinician, Frank M. Longo, MD, PhD who presented “Alzheimer’s Prevention & Treatment: Where Are We Headed?” Dr. Longo is a Professor and Chairman of the Department of Neurology and Neurological Sciences at Stanford University School of Medicine and founder and Chairman of biopharmaceutical firm PharmatrophiX. His team’s work was featured on the cover of Time Magazi
Pet Scan | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Conferences … therapeutics lewy body dementia ltd. m3 biotechnology medicare melvin r. goodes prize memories matter mild cognitive impairment misfolded proteins mitochondria & metabolic function mri multiple scleroris neuroimaging neurolucent neuroprotection neurotherapia neurotransmitters new staff new trustees nyc marathon oryzon genomics partnership pet scan pharmatrophix policy prevention prion disease proteostasis psychogenics repurposing rexceptor rodin therapeutics runners for alzhe … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
Neurodegenerative Disease Therapies | PharmatrophiX | David Setboun, Pharm.D., MBA | 78 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
Conference | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Conferenc … therapeutics lewy body dementia ltd. m3 biotechnology medicare melvin r. goodes prize memories matter mild cognitive impairment misfolded proteins mitochondria & metabolic function mri multiple scleroris neuroimaging neurolucent neuroprotection neurotherapia neurotransmitters new staff new trustees nyc marathon oryzon genomics partnership pet scan pharmatrophix policy prevention prion disease proteostasis psychogenics repurposing rexceptor rodin therapeutics runners for alzhe … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
PharmatrophiX - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailing l … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
World Orphan Drug Congress USA 2027 | Why attend Toggle navigation World Orphan Drug Congress USA 2027 10 - 12 May Thomas M. Menino Convention & Exhibition Center, Boston home Why Attend Our Story Networking Event App 2026 Highlights Supporting Partners CPD Accreditation Sustainability Conference Past Speakers Apply To Speak Agenda Overview Poster Application Speaker FAQs Sponsor & Exhibit Why Sponsor / Exhibit Apply to Sponsor / Exhibit Past Sponsors & Exhibitors prospectus floor plan Start-Up Zone BioPharma Showcase WODC Europe FAQ Register Now - Super Early Bird Tickets VIP Pass … ntion & Exhibition Center | Boston, MA SECURE YOUR DISCOUNTED TICKET APPLY TO SPEAK/SPONSOR/EXHIBIT DOWNLOAD PROSPECTUS Premium Conference Learn from world KOLs in rare diseases on the latest in AI & digital health, gene therapy, clinical trials, patient access and more. Ensure that you are equipped with the most recent policy and governmental changes in OMP legislation and HTA. ➤ Busy Exhibition With a footfall of 1,500+ attende … oni Allmon Vice President, Market Access & Health Policy Magnolia Market Access Grant Castor Chief Business & Commercial Officer Sentynl Therapeutics Lauren Kopsick Founder & Executive Director The Healthcare Navigation Project Augusta Elizabeth Koroma Chief Executive Officer Sickle cell Intervention U.K Connie Lee Chief Executive Officer Alliance to Cure Cavernous Malformations Amanda Moore VP, Program Leadership & Clinical Operations Abeona Therapeutics Julia Pian Senior As
Pharmatrophix | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Confer … therapeutics lewy body dementia ltd. m3 biotechnology medicare melvin r. goodes prize memories matter mild cognitive impairment misfolded proteins mitochondria & metabolic function mri multiple scleroris neuroimaging neurolucent neuroprotection neurotherapia neurotransmitters new staff new trustees nyc marathon oryzon genomics partnership pet scan pharmatrophix policy prevention prion disease proteostasis psychogenics repurposing rexceptor rodin therapeutics runners for alzhe … ped by Frank Longo, MD, PhD. announcements November 8, 2016 $1.5 Million in New Grant Funding for Promising Treatments The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million. blog February 25, 2016 Alzheimer’s Drug Featured in Time Was Made Possible by the ADDF Grantee Dr. Frank Longo's promising new drug to treat Alzheimer's is on the cover of Time magazine. announcements January 5, 2016 Fi … nnouncements September 16, 2015 Dr. Frank Longo Wins Inaugural Melvin R. Goodes Prize Dr. Longo's pioneering approach may soon lead to new disease modifying drugs. Alzheimer's Drug Discovery Foundation A GuideStar-Rated Charity 57 West 57th Street, Suite 904 New York, NY 10019 [email protected] 212.901.8000 © Copyright 2026. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3). Donate Contact Us 2023 Financials Careers State Disclosures … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention
NANOSYMPOSIUM - Society for Neuroscience EN English Deutsch Français Español Português Italiano Român Nederlands Latina Dansk Svenska Norsk Magyar Bahasa Indonesia Türkçe Suomi Latvian Lithuanian český русский български العربية Unknown Login to YUMPU News Login to YUMPU Publishing TRY ADFREE Discover products News Publishing Magazines Create ePaper Login to YUMPU News Login to YUMPU Publishing × Attention! Your ePaper is waiting for publication! By publishing your document, the content will be optimally indexed by Google via AI and sorted into the right category for over 500 million ePap … 7: ABSTRACT NUMBER STATEMENT 59.11 J. Page 98 and 99: ABSTRACT NUMBER STATEMENT Grant; G. Page 100 and 101: Convention Center Floor Plans San D Page 102 and 103: San Diego Convention Center Floor P Page 104 and 105: AISLE LL8 LL9 LL10 LL11 L12 M M7 M Page 106 and 107: Hotel Floor Plans Manchester Grand Page 108 and 109: Marriott Hotel & Marina Floor Plan Page 110 and 111: Hilton San Diego Bayfront (continue Page 112: Wednesday to Saturday november 10-1 show all × Sh
World Orphan Drug Congress USA 2027 | Boston Toggle navigation World Orphan Drug Congress USA 2027 10 - 12 May Thomas M. Menino Convention & Exhibition Center, Boston home Why Attend Our Story Networking Event App 2026 Highlights Supporting Partners CPD Accreditation Sustainability Conference Past Speakers Apply To Speak Agenda Overview Poster Application Speaker FAQs Sponsor & Exhibit Why Sponsor / Exhibit Apply to Sponsor / Exhibit Past Sponsors & Exhibitors prospectus floor plan Start-Up Zone BioPharma Showcase WODC Europe FAQ Register Now - Super Early Bird Tickets VIP Pass ven … hibition Center | Boston, MA America's Largest Orphan Drug & Rare Disease Event APPLY TO SPONSOR / EXHIBIT / SPEAK SECURE YOUR SUPER EARLY BIRD RATE 250+ Speakers 1,500+ Attendees 80+ Exhibitors 16 Streams of Content Breaking barriers & fostering collaboration to help the rare disease community The World Orphan Drug Congress USA brings together the leading pharmaceutical and biotechnology companies, government and regulators, patient advocates, payers, investors, and solution … he rare disease and orphan drug space from top thought leaders in the industry. APPLY TO SPEAK THE EXHIBITION Discover innovative products and solutions revolutionizing the future of rare disease. APPLY TO SPONSOR/EXHIBIT NETWORKING Connect with fellow rare disease and orphan drug advocates from around the world – all with a shared passion to improve the lives of rare disease patients. GET YOUR TICKET Sponsor the World Orphan Drug Congress USA Get your product or solution in … oni Allmon Vice President, Market Access & Health Policy Magnolia Market Access Grant Castor Chief Business & Commercial Officer Sentynl Therapeutics Lauren Kopsick Founder & Executive Director The Healthcare Navigation Project Augusta Elizabeth Koroma Chief Executive Officer Sickle cell Intervention U.K Connie Lee Chief Executive Officer Alliance to Cure Cavernous Malformations Amanda Moore VP, Program Leadership & Clinical Operations Abeona Therapeutics Julia Pian Senior As … l Affairs Strategy, Rare Disease Sumitomo Pharma America Inc VIEW PAST SPEAKERS APPLY TO SPEAK The Start-to-Finish of Orphan Drugs From regulation and policy to global pricing and gene therapy PATIENT DATA PATIENT DATA With so few patients, patient data/real-world-data (RWD/RWE) is the key element to advancing the rare disease space. What are bes
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 20 0 R 21 0 R 22 0 R 23 0 R 29 0 R 30 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x�� ksܶ�f� ����H A|x ���jv9?�f;�g3����S�{9W����˿ �� ̅�� �Λ� ~D�w�6=���"�0Ws�� #!�$����J�+v�\ � @�i��G�[@4�ދ#C�0� �+NMS?�X�k��ȏ���� V�_~��p�7�2���2�It∈a������(B t���� � ���z� r ��!��� �](���D_�-�yj��^4�Q[�(�v�Uëx���zs ���O����N�,,H��F )=�+�v� �ؗr � (��ۅ�����Bk����������.T@(�HgK�E�E�sT�jFJ���;���K�
Team - Red Tree Venture Capital Skip to content Menu Menu Home Our Approach Portfolio Team About Us Venture Labs News Menu Home Our Approach Portfolio Team About Us Venture Labs News Team Red Tree Venture Capital was founded in 2020 by Heath Lukatch, Ph.D., and Jennifer Cochran, Ph.D., two experienced life science industry veterans with deep connections to the West Coast academic and biopharma ecosystems. The firm is led by an accomplished team with decades of combined experience investing in, founding and operating life science companies across various stages, sectors and therapeutic areas. T … ably, the recent acquisition by Novartis of Excellergy Therapeutics, a Red Tree Fund I portfolio company where she served as a founding investor and board member, underscores her ability to advance innovative science from company seed investment through exit. Jennifer Cochran, Ph.D. is a Founder and Chief Scientific Advisor... Jennifer Cochran, Ph.D. Co-Founder and Chief Scientific Advisor Jeremy Caldwell, Ph.D. Position: Managing Director Dr. Caldwell is a Managing Director … theon Ventures. Cassie started her career as an Analyst at Callan Associates, a fund sponsor consulting firm and then moved onto trading operations at Algert Global LLC, a quant based hedge fund. She holds a B.A. from the University of California, Davis. Cassie is VP of Investor Relations at Red Tree Venture... Cassie Lue VP of Investor Relations Ariell Ortega Position: Executive Assistant Ariell Ortega is the Executive Assistant to the Red Tree team in San Diego, bringing th … Massachusetts Institute of Technology, where she also completed a postdoctoral fellowship in Biological Engineering. Her research and translational interests span protein-based drug discovery and development for applications in oncology and regenerative medicine, and development of new technologies for high-throughput protein analysis and engineering. Dr. Cochran is a serial innovator and brings extensive company formation and entrepreneurial experience, having founded sever … m Stanford (2000). Deisseroth completed medical internship and adult psychiatry residency at Stanford, is board-certified by the American Board of Psychiatry and Neurology, and founded and directs the Stanford Human Neural Circuitry (HNC) program. In addition to resolving the structural and functional mysteries of natural light-gated ion channels
%PDF-1.4 %���� 10455 0 obj > endobj xref 10455 47 0000000016 00000 n 0000002781 00000 n 0000002945 00000 n 0000004576 00000 n 0000004974 00000 n 0000005822 00000 n 0000006171 00000 n 0000006812 00000 n 0000007611 00000 n 0000007896 00000 n 0000008571 00000 n 0000008687 00000 n 0000008953 00000 n 0000009594 00000 n 0000009857 00000 n 0000010641 00000 n 0000010904 00000 n 0000011994 00000 n 0000012139 00000 n 0000012870 00000 n 0000012901 00000 n 0000014042 00000 n 0000015115 00000 n 0000016283 00000 n 0000017337 00000 n 0000018502 00000 n 0000018962 00000 n 0000019347 00000 n 0000020424 00000 n … 36e83dee750 xmp.did:163f09c3-5e09-43be-9342-3d796332cd4f default converted from application/x-indesign to application/pdf Adobe InDesign 18.5 (Macintosh) / 2025-01-29T10:12:27+01:00 application/pdf Adobe PDF Library 17.0 False endstream endobj 242 0 obj > endobj xref 0 10455 0000000000 65535 f 0000159140 00000 n 0000160726 00000 n 0000168798 00000 n 0000169816 00000 n 0000178902 00000 n 0000180487 00000 n 0000188031 00000 n 0000189049 00000 n 0000197592 00000 n 0000199178 000
PharmatrophiX | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Confer … t to PTX focused on the NGF mimetic program. This year, PTX was chosen for the "Fund-a-Biotech" program for the ADDF connoisseur's dinner to garner support for a different earlier-stage program at PTX, the BDNF mimetic program. This new and exciting program seeks to develop drug candidates that mimic brain-derived neurotrophic factor (or "BDNF"), a protein that protects brain cells and is deficient in normal aging and in Alzheimer's disease patients. PTX's "BDNF mimetics" hav … intellectual property status and optimize blood brain barrier penetration; and application of a prototype BDNF mimetic to an Alzheimer's mouse model. View all funding to this organization (6) View all funding to this investigator (8) GET IN TOUCH [email protected] 212.901.8000 Alzheimer's Drug Discovery Foundation A GuideStar-Rated Charity 57 West 57th Street, Suite 904 New York, NY 10019 [email protected] 212.901.8000 © Copyright 2026. The Alzheimer's Drug Di … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
Login | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer'
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
PharmatrophiX | The Org Platform Enrich Pricing Log in Sign up PharmatrophiX 0 followers PharmatrophiX is a biotech company focused on developing therapeutic drugs to prevent neurodegenerative diseases. Industries Biotechnology , Health Care + 1 Headquarters Raleigh, United States Employees 1-10 Links Org chart Teams Offices Positions ( 6 ) Unverified Org chart Anne Chun Longo CEO 1 Anne Chun Longo Collapse John T. Autrey Chief Financial Officer 0 Board & advisors Frank Longo Chariman & Founder Jeffery L. Cummings Advisor Eric Reinman Advisor Lon Schneider Advisor Teams This company
%PDF-1.7 %�������������������������������� 1350 0 obj > endobj xref 1350 134 0000000044 00000 n 0000003696 00000 n 0000004044 00000 n 0000004075 00000 n 0000004174 00000 n 0000005202 00000 n 0000026846 00000 n 0000026904 00000 n 0000026955 00000 n 0000027023 00000 n 0000027066 00000 n 0000053151 00000 n 0000053274 00000 n 0000053794 00000 n 0000053927 00000 n 0000054449 00000 n 0000054580 00000 n 0000055120 00000 n 0000055311 00000 n 0000055609 00000 n 0000055676 00000 n 0000055906 00000 n 0000056562 00000 n 0000056991 00000 n 0000057292 00000 n 0000057370 00000 n 0000057629 00000 n 0000058331 … 2.014583 32.014583 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 application/postscript CROSSMARK_Color_txt_100x100.eps Rakesh Masih xmp.did:9CC21C1691CBE711A2D1A544EA6CD4C5 xmp.iid:9CC21C1691CBE711A2D1A544EA6CD4C5 uuid:3d06d59a-b8c0-4d72-9d2d-9d778c160cc4 xmp.iid:c9e3282a-5173-c243-80b5-64480c96b046 xmp.did:c9e3282a-5173-c243-80b5-64480c96b046 uuid:3d06d59a-b8c0-4d72-9d2d-9d778c160cc4 saved xmp.iid:c9e3282a-5173-c243-80b5-64480c96b046 2017-09-14T12:19:21+05:30 … 2017-09-14T12:19:21+05:30 Adobe Illustrator CC 2015 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:9CC21C1691CBE711A2D1A544EA6CD4C5 2017-11-17T17:46:05+05:30 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator endstream endobj 1361 0 obj > endobj 1362 0 obj > stream h��Kn�0��>�l+R�� I����E�MwM1�`J$(R}�,z�^�� B�d�@�� ������ķ�f|#,X�U^&���/�,�Oé?��ο�x�}��݆� ަ … ��� �C�+� �]Y���w�_ s � endstream endobj 87 0 obj > endobj 88 0 obj > stream application/postscript Print 2025-03-07T17:32:03+05:30 2025-03-07T17:32:03+05:30 2025-03-07T17:32:03+05:30 Adobe Illustrator 25.4 (Windows) 256 72 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fH … 18 Adobe PDF library 15.00 endstream endobj 89 0 obj > endobj 90 0 obj > stream application/postscript Print 2025-03-07T17:31:47+05:30 2025-03-07T17:31:47+05:30 2025-03-07T17:31:46+05:30 Adobe Illustrator 25.4 (Windows) 256 68 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/
Kathy Huff - Rankin McKenzie Skip to content We’re Hiring Why Partners Choose RM We’re Hiring Why Partners Choose RM How We Help Clients Fractional CFO Fractional Controller Free Financial Operations Assessment CFO Partners Client Success View our Clients Case Studies We’re Hiring Why Partners Choose RM Executive Resources Are you Ready for a CFO? Schedule Consultation How We Help Clients Fractional CFO Fractional Controller Free Financial Operations Assessment CFO Partners Client Success View our Clients Case Studies We’re Hiring Why Partners Choose RM Executive Resources Are you
Alzheimer's Drug Discovery Foundation Funds PharmatrophiX to Develop Drugs to Prevent Neurodegenerative Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Alzheimer’s Drug Discovery Foundation Funds PharmatrophiX to Develop Drugs to Prevent Neurodegenerative Disease January 24, 2008 | 1 min read Twitter LinkedIn Facebook Email Print NEW YORK, NY--(Marketwire - January 24, 2008) - The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is pro … oundation (ADDF) announced today that it is providing a biotechnology founder's grant of $300,000 to PharmatrophiX, a start-up biotechnology company dedicated to developing a drug to prevent neuronal degeneration and improve brain function. Twitter LinkedIn Facebook Email Print LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy June 26, 2026 · 4 min read · Heather McKenzie Lay … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Dr. Frank Longo Wins Alzheimer's Drug Discovery Foundation's Inaugural Melvin R. Goodes Prize For Researchers Working In Alzheimer's Drug Discovery - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug De … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Dr. Frank Longo Wins Alzheimer’s Drug Discovery Foundation’s Inaugural Melvin R. Goodes Prize For Researchers Working In Alzheimer’s Drug Discovery September 16, 2015 | 5 min read Twitter LinkedIn Facebook Email Print NEW YORK , Sept. 16, 2015 /PRNewswire-USNewswire/ -- Physician-scientist Frank M. Longo , … l winner of the Alzheimer's Drug Discovery Foundation's (ADDF) Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery, the first prize to specifically recognize researchers working in novel and promising areas of Alzheimer's drug discovery. Dr. Longo is Professor and Chairman of the Department of Neurology and Neurological Sciences at Stanford University School of Medicine and founder and Chairman of biopharmaceutical firm PharmatrophiX. "It is fitting that Dr. L … X. "It is fitting that Dr. Longo is the recipient of the first Melvin R. Goodes Prize, as his pioneering research has significant potential to result in successful disease-modifying treatments for Alzheimer's within the next few years," said Howard Fillit , MD, Founding Executive Director and Chief Scientific Officer of the ADDF. "By establishing this prize, we seek to celebrate the research of scientists such as Dr. Longo, whose drug discovery work often goes unrecognized, a … e drug discovery work often goes unrecognized, and provide them with a monetary award, so that they can continue taking bold chances in pursuit of novel and effective treatments." Dr. Longo and colleagues developed an innovative approach to identifying and developing small, orally available drugs that mimic the function of normal brain proteins (
%PDF-1.7 %���� 1 0 obj > endobj 2 0 obj >/Font >/ProcSet[/PDF /Text /ImageB /ImageC /ImageI]/XObject >>>/StructParents 0/Tabs/S/Type/Page>> endobj 4 0 obj > stream x���gS�i���?�֚�nl��s�9�L9'I !� @�llI���v�ힵ�ήG¡g���ު����:|]����L� �b�j��&,��$ꠈZ��: ӄ�h�D'��H�Q�2��o@��(��5A8M��� $0�h�z� ��0�ܕ������CJ��J�9 TX%z��8 � 08V�\��i�O{�O�?;�N8�O:�K�*K�@�A?9��t�J��d�\;�i�+j!B���Ƒ�Nj��Y�B�s#�zPgF�%�?�yr q� ;5- @Ύ�� �.�W�E��%�� ;6��y���� d�qʍ���yqb qbyҋ8=�,�@� �K������ď(�!N{�����q� �� W:Q(P [��1e�r?��������aR�U !N"�A���V Su�`�ta�"$O���\���Q�T��6Hg8 … -�w��4k�d � ݉]�ͦe(���v� �����Db��J�\?QL;�����'y4�F��PBFB;'�N���n/�U��4͔�K�%��rFp�f�ha�B�?m�i�8 S��bю�$Fn#k#�+� '�w^:���t�e阫�k�?��g�%��%ZzG�*^���x�}]6F�y�� 8�Lp� ��aI�ȷ�4;�v��̿����{�*x��O��=���������О�E;[�Z$�(g��qO��[oL���#.�JJy��F��j�.��^�Y�뻽�BY^��ʪ9 Ya�(+�������{��Z�e�ݪ�.���n��Y��� :��E��ٷ��� u�ߪ�%�Č0�zĤ��揙�8d�|���a���ܼ��o�5i�PVƕ����"��×�hx�f����j�/��H�|1���W��ɽv'iˁ��s=��_�m��N6��i8z3s�fƈ-���W��X�k7� ��� T��N�����iנ]h�m=���yDQv]0��5��o� … ���~������T����q��|L{rF[xA{xF{pB� ���Ɍ�b�0W �}89 U�(ݿ��z�,��3���* ����j�hu+��Rfp ۴�����fN e�� }oz��� �3������������ y�? ||�e9�c ڹ�ҵ���N�����Vm�G� ���������#�ȶyp�>�潷�ܮ��]ۻl_�iZ�n|RۼR�\���|��(uv�:;�]�ͮ�vsm��צ(��w��{��!o�dI�ti�dQ݈7��,n�XK2 ����� ��/ �T���u �I����N��eֺ�Z�M㶫 ��2ck�����Z����y�� �%�1��L��r;*����K��#c���0 ����mOJ@����=�A'Q(x,���@Q��;��(4�����TTZV&��d ��X�U�Lz�ݢt:�.������t����X F$'��d����i�T"�ςⳠ�HA��it����1$*�@L"�r�p-g��������,,�N��J�
%PDF-1.4 %���� 250 0 obj > endobj 253 0 obj > stream x���x[��?~� Z�m�ְ-[�dK�-Y��Gb'��xdOg��! 2HH��Z�$̦@!Ĭ��ҁKK -�BK7�6mi�����{���a������ G?�j͢d�J�����V/غ���C�I�>���8U�>���{t� ��d+!����_���� ��k��Y� ߦ�����!��F:ҟ ����%o%93M�ύ==]���8��cc��]�� &c����^�~ʽ�c�I���q:�����H>)�6�hs&�9��y���5x��6 m�6S��L���_}� !�q��~���C�W� ?����t��U��?6��]�����������ħ��d�����UDKe�r�~r��H�Or��B�$� d�H��?@W'H+��I� d����#�p�F�x�����G����}gHK�SDK�ysK�Z��Ӻ��4� �b�(t@�/�i;ͻ��s�r� �\|(�-gقŧ;�K ysN�i����郎� C�hq��P�#`;k����Bnak�����9�yw�`����-�� -C6�#����=���o�9���,U�N�x�
Directory – OnBoardNC Skip to content Search for: Leadership About Us Directory Members Only Contact Search for: Directory dloconnor 2023-04-24T17:55:17+00:00 OnBoardNC Directory Our experience spans industries and sectors – healthcare, financial, technology, energy, consumer products, services, education. You’ll see leaders from every type of organization — publicly-traded, closely-held, global, mid-market, non-profit. Loading… We are a non-profit organization focused on shrinking the boardroom gender gap since 2015. We identify and onboard highly qualified, board-experienced fema
%PDF-1.5 %���� 7 0 obj > endobj 73 0 obj >/Filter/FlateDecode/ID[ ]/Index[7 124]/Info 6 0 R/Length 262/Prev 3330280/Root 8 0 R/Size 131/Type/XRef/W[1 3 1]>>stream h�bbd```b``a� `� ɽ L>��� �+ L�ŋ�l ��Q��D2��3��L)ɤa4}�������zu��`��o�� ��̞��8X� �^a0�2�%�`5� ��X| �,>6�d��2X � [���d�}zLn��f��lF`��" ��w�fCB�3�� 2���d~l$9N~�����$��� �� ��#b~� x bǀlgYud�� y�)�� #��!��8JR����t�$@�a�5� endstream endobj startxref 0 %%EOF 130 0 obj >stream h�b``p```�```0ڵ�01 G��300�0�4pg1�L��eXX��̰Ȁ����) � l= ���cx�4����]��� �� ��y�� 83Hp�3}`�� ����An��e�-� ��� … 6352068118083F69E3CA3B07F xmp.did:1E36391B1B2068118083884A2A50B453 default 7401 application/pdf Adobe PDF Library 9.9 False endstream endobj 47 0 obj >stream H��T]o�0}���`��ۤ �*U�6������cZT��m��w�P�d�6�k�{�}�1�^�u[���M�e�EP؝��= �����Ew�y� ɽu�,cN_q��Xܤi��$\p�&*R�H$�d��ۏ ������:�a�E�!����~ ��u/L���%I("�?4z��O#�D��^�� �m���v!��@f������Xٚ�q���=���������>O)��vΌ[-�F sĜ�듏���뮜�A �ʇ���*� �u$U5���)W%���d���W،'�%� >stream H��V]��6}���`e_'@ "#e�#�vH� … d:F1F65D58BC216811822AAD6A102363D7 2013-03-27T14:26:23-04:00 Adobe InDesign 7.0 application/pdf Adobe PDF Library 9.9 False endstream endobj 2 0 obj >stream h�2U0P���w�/�+Q0���L)�����T��$�����w � endstream endobj 3 0 obj >stream h�2S0P���w.JM,���sI,I�p�2204606274127��50Q70Pׄ��/�pL�OJU��sI-�L�Sp6U��0�3������O�0��委&��L pqS��L*J,�T�Գ��)J,(HM�wK�)N��0�[-e endstream endobj 4 0 obj >/Filter/FlateDecode/ID[ ]/Info 6 0 R/Length 39/Root 8 0 R/Size 7/Type/XRef/W[1 3 0]>
%PDF-1.7 %���� 2367 0 obj >stream h��Z�r۶���|L����u��Y�c�v��'��-�6�%Q�('��w� P�hR���� ���&�־A�R�# W��QʣB�(/D�E5]�U�"*���m\�A@� � ��\8��5����U4���DcK���� $�i�Д\G�?�����t:�9�y�AHsh��\9� IHL�C���c�%�x.��\� }z=O;^�Qϣע7�|��>� �c �~r]���� �K�� „�[(]� ��I����H����J�I���"^=ː$�#'�&(�N�5�H'�xK0Q Ĵ���#�Xg�� �*�� |Z}M�a����'�W.�~+ ��j1"��x����(F�����y%���#@s~��;�'�{�oG�����P *Ѐ@��j�{�{CߔiDͲtП^]�y�� �a��b4H��I�w:��'q�4N�q�ݛ7W*�6�#F����i x][(e�__��t�L�"�G�3���1�ݣϿB������`��+�r���0�Fܖ���F=�v\�j�i2�K�6N� /�(�� �=�%U�nA*G�P���4��k/��pZ�O�H�0s��̹Mh�H|�' … -03-19T21:47:25-04:00 2026-03-19T21:47:25-04:00 Adobe InDesign 20.5 (Macintosh) application/pdf uuid:ebd7e764-d730-6046-930f-3d9a8214cb9b uuid:7a2d3e28-080b-8047-9b56-4ea46de3e8a6 Adobe PDF Library 17.0 endstream endobj 8 0 obj >stream H��Wێ���k�� �@�I���5�k�� �u0Z�!=T�H�d�lR��'9���L�@��>u;U �Q��_��c���^����i� w)-�a���vnڬ��Jz�w����^��u�(��ٿ���?�/���W�$z� ����_��mb6��"��+%)�)��������;���cg��f�9��_1e,w�6�ni�ۅ�]!��L�w�Ym�%���i�N F�� �6�'C[h �� ����hҶg�G�~|Ջ&-ޝ� … "vÂ��{�� ��g��ȍN&�����m � �,dvD`H�_4��@�� P|��UӍ�p7A�*�۰ f6V�?&�%����arn�ԭRfp�V�d�ל��y�p��r3��=su��(����O��p9��߲�R��[E��zἶ����/J|��ļ�S4����sTۤ��fARS"�h��z>�ߝjt~����M� ��ƪ;j��s܃ 6%k�)'��BNV��\����vLH,�y�- ��i�N�� t+IJp�>*�/�5Xl�ψC���i0�atU�B���`�J=��' �4pD�Ӫj�7�mXo�!ʜ�vb]Vτ�'�ى��o��B�������"�x/ +��&kg���da��!zJ�+[���j�iG�/H���Q��1BS䝩�9�{�ף�4�8!g��%�ݽ��i|*u� OT�s�BrmJ��h�� ^�=`�'�`��-%�� 5P�4�y�Ίo:H ��5�I��75���Z��Q-��2�X �0����^ � … ��EF��q�rf� CįQ9ZY�$r!���6m �)�4� ��V�9�k�J�$#�� Fь�X��٥�C��p�[��ģ)C���S�;rFP#�I�m�K�G ɺ��z���j>>��X�9,�ZL-j��Ib�k��ȉ8�˚?v�t���� �x������P�IO}�_ay@ ��:����|Ve�6�����ubd/e�3 T� Sؓ�7X����?MM�!���Լu�O��t����P Cbt;���i����ް��a��@gW��#�@��4c�9.D���o� z2>M�5��i�~�u0� �q�s �wQ�9�ǸLt��삟�Mz)>���kɝ���I�;���io�"���U)��]$Y���L >� $����$T����:gUo$���UK���,�C�`sCMAJMÄ��K��C(��g]���ٮ9�s�U�G�0?����L�5��� �QM%��0O�l��5&���`�Ƒ 1,��x�'���{��k+�mY�}��� … :1ee3fc05-7066-4f2a-9a5a-f8a2f6c2d64e uuid:90bd21e5-c102-5b45-9c15-3e63b325b693 application/pdf Adobe PDF Library 17.0 endstream endobj 2074 0 obj >]/Cn[ >/Fi[ >]/P[ >/JTF 0/T >/5th >/6th >/7th >/8th >/9th >/Black >/Crease >/Cyan >/M1 >/M2 >/M3 >/M4 >/Magenta >/Yellow >>>/TO[/Cyan/Magenta/Yellow/Black/Crease]>>/T true>>/TP >>>/TR[ >]/W[0 0]>> >/J
--> Content not found Home About Terrapinn Work for us Login Content not found :( Sorry but the page you were looking for has not been found. We suggest you navigate back here up a level: /conference/world-orphan-drug-congress-usa  » World Orphan Drug Congress USA is the leading rare disease event advancing orphan drug development, clinical trials, regulatory strategy, market access, and patient advocacy. Join biotechs, pharma, payers, and regulators to Register » Brochure » Get In touch: [email protected] What can you do now? Well you could try going back to the last pa
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Dementia Discovery Fund | London Asset Manager | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home Profiles Dementia Discovery Fund Asset Manager Updated: Jun 3, 2026 Dementia Discovery Fund The Dementia Discovery Fund is a collaboration between charity, industry, and government, based in London, United Kingdom. It has made 36 investments,... Dementia Discovery Fund The Dementia Discovery Fund is a collaboration between charity, industry, and government, based in London, United Kingdom. It has made 36 investments, including a Series A investment in Leal Therapeutics … s, including a Series A investment in Leal Therapeutics on August 26, 2025. The fund has facilitated 3 portfolio exits, with Caraway Therapeutics exiting on November 21, 2023. Website dementia-discovery-fund.com LinkedIn linkedin.com/company/dementia-discovery-fund Overview Investment focus Team Deals Network General information Firm type Asset Manager Year founded 2015 AUM Undisclosed Location Region Europe Country United Kingdom City London Corporate office London, United K … nal offices Amsterdam, Netherlands · Boston, MA, United States Principals Angus Grant CEO Tetsu Maruyama Chief Scientific Officer Sector focus Digital Health AI/ML Frequently asked questions Who runs investment decisions at the Dementia Discovery Fund? Angus Grant serves as CEO and leads the investment team, supported by Chief Scientific Officer Tetsu Maruyama. Grant joined in 2021 from a career spanning executive R&D roles at Roche and Celgene. The fund's Investment … visions of its pharmaceutical limited partners. How does the Dementia Discovery Fund source proprietary deal flow? The fund sources opportunities through the academic neuroscience networks of its LPs' R&D organizations, direct relationships with university technology transfer offices in the UK and US, and referrals from its Scientific Advisory Board. Its pharma backers — including Biogen, Eli Lilly, and Johnson & Johnson — provide visibility into preclinical asse … ritized internally but viable as standalone ventures. Is the Dementia Discovery Fund structured as a single family office or does it operate more like a venture firm? It operates as a specialist venture capital firm. The vehicle was established in 2015 as a public-private partnership, not a family office. Its limited partners include the UK Depar
Market Research Reports and Consulting – Global Insight Services Alzheimer's Disease - Drug Pipeline Landscape, 2023 US: +1-833-761-1700 [email protected] Submit Queries Home Reports Automotive & Transportation Chemicals & Materials Consumer Goods Energy & Natural Resources Food & Beverages Manufacturing & Construction Medical Devices Pharmaceuticals Semiconductors & Electronics Technology, Media, & Telecom Services Syndicated Reports Custom reports Consulting Services Subscriptions Insights Analyst Insights Press Releases Contact Us --> Hom … gh primary sources, allowing for an overall market value to be derived for each application. Year-over-year (Y-o-Y) growth rates were applied to forecast market values for each application, reflecting a trend of slow, steady, or growing demand based on actual growth rates in each sector. The compound annual growth rate (CAGR) was calculated by analyzing industry penetration, supply and demand trends, and end-user industries' needs for the market. The market was further verifi … ted based on secondary research, including splits by battery voltage, type, and application. The demand from companies in different application segments was analyzed to assess overall market trends. Ongoing and upcoming projects implementing the market were tracked, and these insights were used to estimate market size based on key developments. Several discussions with industry leaders were conducted to validate the split of market segments by voltage, type, and application.
US9271986B2 - Crystalline forms of neurotrophin mimetic compounds and their salts - Google Patents US9271986B2 - Crystalline forms of neurotrophin mimetic compounds and their salts - Google Patents Crystalline forms of neurotrophin mimetic compounds and their salts Download PDF Info Publication number US9271986B2 US9271986B2 US13/509,470 US201013509470A US9271986B2 US 9271986 B2 US9271986 B2 US 9271986B2 US 201013509470 A US201013509470 A US 201013509470A US 9271986 B2 US9271986 B2 US 9271986B2 Authority US United States Prior art keywords methyl morpholinoethyl amino pentanamide crystalline f … sentation as to the accuracy of the status listed.) Active , expires 2031-11-19 Application number US13/509,470 Other versions US20130005731A1 ( en Inventor Rajgopal Munigeti Frank M. Longo Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Pharmatrophix Inc Original Assignee Pharmatrophix Inc Priority date (The priority date is an assumption and is not a … sted.) 2009-11-12 Filing date 2010-11-12 Publication date 2016-03-01 2010-11-12 Application filed by Pharmatrophix Inc filed Critical Pharmatrophix Inc 2010-11-12 Priority to US13/509,470 priority Critical patent/US9271986B2/en 2012-08-29 Assigned to PHARMATROPHIX, INC. reassignment PHARMATROPHIX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LONGO, FRANK M., MUNIGETI, RAJGOPAL 2012-09-07 Assigned to Ricerca Biosciences, LLC reassignment Ricerca … on of US20130005731A1 publication Critical patent/US20130005731A1/en 2016-03-01 Application granted granted Critical 2016-03-01 Publication of US9271986B2 publication Critical patent/US9271986B2/en Status Active legal-status Critical Current 2031-11-19 Adjusted expiration legal-status Critical Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss KDVZXYGMIBUVHO-IOLMCIFPSA-N CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1.CC[C@@H](C)[C@H](N)C(=O)NCCN1CCOCC1.CC[ … of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide described throughout the application including a crystalline form of any single enantiomer of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide, a mixture of any two enantiomers of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide, a mixture of any three enantiomers of 2-amino-3-methyl-N-(2
Dolby Family Ventures | Portfolio Portfolio Philosophy People News Portfolio Our portfolio companies are addressing complex science and engineering challenges across the life sciences and technology fields. All All Life Sciences Technology Exits Precision Neuroscience Funding a diversity of approaches to complex neuroscience challenges across neurodegeneration, psychiatry and neurotech. Our core focus is disease-modifying treatments for Alzheimer’s Disease and Depression, but given the common and converging nature of underlying etiology, we fund across the spectrum of neuro disorders. Neurodeg … technology into “smart” implements capable of autonomously managing fertilizer application resulting in cost savings, increased yield, and reduced runoff. Active Soil Action Soil Action's sensor and AI-driven platform delivers real-time soil chemistry analysis — on-tractor, in-the-field — transforming variable rate technology into “smart” implements capable of autonomously managing fertilizer application resulting in cost savings, increased yield, and reduced runoff. Ac
%PDF-1.4 %���� 59 0 obj > endobj xref 59 58 0000000016 00000 n 0000001971 00000 n 0000002034 00000 n 0000002312 00000 n 0000002355 00000 n 0000002386 00000 n 0000002494 00000 n 0000002623 00000 n 0000012269 00000 n 0000012467 00000 n 0000012841 00000 n 0000013085 00000 n 0000030184 00000 n 0000030378 00000 n 0000030904 00000 n 0000031263 00000 n 0000041555 00000 n 0000041749 00000 n 0000042047 00000 n 0000042242 00000 n 0000048719 00000 n 0000048927 00000 n 0000049267 00000 n 0000049497 00000 n 0000049539 00000 n 0000050042 00000 n 0000050587 00000 n 0000062282 00000 n 0000062482 00000 n 00000 … :004e23a6-50f6-11e8-0000-fd7201d7d1e5 uuid:2a7e8f0e-bf11-4b1d-b630-1c4e48bbc624 application/pdf Microsoft Word - ACW070518 jhowe endstream endobj 58 0 obj > endobj xref 0 59 0000000000 65535 f 0000171258 00000 n 0000171430 00000 n 0000171460 00000 n 0000176808 00000 n 0000176980 00000 n 0000177010 00000 n 0000185961 00000 n 0000186155 00000 n 0000186185 00000 n 0000186216 00000 n 0000192000 00000 n 0000280512 00000 n 0000280709 00000 n 0000280740 00000 n 0000280772 00000 n 00
Novartis announced that all conditions to close its acquisition of MorphoSys have been fulfilled, securing 79.6% of our total share capital and surpassing the minimum 65% shareholder acceptance… | MorphoSys | 14 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic … ition. Safety and efficacy, guess we will know more by second half of 2024 when application is submitted to FDA. Will be interested in seeing the ASCO presentation on phase III. Like Reply 1 Reaction Philip Hemme 2y Report this comment 👏✅ Congrats MOR team Yimin He, Samuel White , Thomas Biegi Like Reply 2 Reactions 3 Reactions Elena Rizova MD,PhD 2y Report this comment Great news! Congratulations Jean Paul for your leadership and resilience to bring in ivatio
Cortexyme Raises $1M Seed Round --> VC DATABASE MOBILE APP VENTURE SEARCH ARCHIVE ABOUT US Your Source for Venture Capital and Private Equity Financings Massinvestor/VC News Daily --> Cortexyme Raises $1M Seed Round Back to Home 2014-10-06 Tweet SAN FRANCISCO, CA, Cortexyme received a $500,000 investment from Dolby Family Ventures as part of $1 million in seed financing to fund their preclinical research. >> Click here for more funding data on Cortexyme >> To export Cortexyme funding data to PDF and Excel, click here Dolby Family Ventures, an early stage venture capital fund, today announced t … folio of Healthcare Technology companies. Dolby Family Ventures is an evergreen fund that invests between $10-20 million per year, with nearly one-third of those investments targeted specifically to Life Sciences, with an emphasis on Brain Health. Dolby Family Ventures invested $2 million in PharmatrophiX, leading a $5.5 million first closing round to fund their continued path to human clinical trials. PharmatrophiX is focused on the development of disease-modifying small mol … nvestment from Dolby Family Ventures as part of $1 million in seed financing to fund their preclinical research. 'After losing my father, Ray Dolby, who battled Alzheimer's disease, my family has committed to pursuing a strategy that combines strategic investments made by Dolby Family Ventures, and philanthropic grants made by the Ray and Dagmar Dolby Family Fund, to help improve the lives of future Alzheimer's patients,' said David Dolby, Managing Director, Dolby Family Vent … nia Pacific Medical Center in San Francisco recently announced the Dolby Family Fund's founding gift to establish the Ray Dolby Brain Health Center, which focuses on helping families with Alzheimer's, and by advancing the science of care through research and education. In 2013, the Dolby family led a capital raise for Cogstate Limited (CGS.AX), one of the leading providers of cognitive performance testing software and services for clinical trials and precision recruitment of … investment syndicate partners at the seed stage of a company's development. The fund honors the legacy of Ray Dolby and his commitment to engineers and their vision to solve the world's toughest problems. Dolby Family Ventures formalizes the Dolby family's ongoing, multi-generational commitment to discovering and supporting visionary entrepreneur
Clinical Trials | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Conf … therapeutics lewy body dementia ltd. m3 biotechnology medicare melvin r. goodes prize memories matter mild cognitive impairment misfolded proteins mitochondria & metabolic function mri multiple scleroris neuroimaging neurolucent neuroprotection neurotherapia neurotransmitters new staff new trustees nyc marathon oryzon genomics partnership pet scan pharmatrophix policy prevention prion disease proteostasis psychogenics repurposing rexceptor rodin therapeutics runners for alzhe … her Wins Alzheimer’s Drug Discovery Foundation’s Prestigious Goodes Prize Michele Gallagher, PhD, is the recipient of the fourth Melvin R. Goodes Prize, which includes a $150,000 award to support the therapeutic development of AGB-101. announcements September 13, 2018 $2.3 Million in New Funding Focused on Novel Biomarkers and Treatments The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies. a … r and two Phase I clinical studies. announcements July 13, 2018 New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy. announcements May 10, 2018 $2.5 Million in New Funding Exemplifies ADDF’s Strate … inton Wins Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize Dr. Brinton has pioneered a promising neurogenesis therapy for Alzheimer’s disease. announcements September 13, 2017 18th Annual Conference on Alzheimer’s Drug Discovery Showcases Non-Amyloid Research Nearly 200 academic and industry researchers came
Executive Team and Scientific Advisory Board --> About Research & Development Neurodegenerative Diseases News & Publications Contact Who we are About PharmatrophiX About Our mission, story, and approach. Leadership Team, board, and scientific advisors Peer Reviewed Funding & Investors Our science Research & Development Research & Development Our science and development philosophy. Pipeline Programs and indications across our development stages. About · Leadership The people behind the science. A clinical-stage team of neurologists, medicinal chemists, translational scienti … of such compounds. Dr. Longo is the inaugural recipient of the Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery. Dr. Longo serves in many advisory capacities including the National Advisory Council on Aging, NIH study sections, editorial boards, foundations, grant review boards and therapy evaluations. Anne Chun Longo Co‑Founder, Founding CEO Read Bio Anne Chun Longo is Co-Founder of PharmatrophiX and served as its Founding CEO from 2006 to 2025. She … eived his medical degree from Oregon Health Sciences University, then completed residency training at NYU in New York and fellowship training at Fox Chase Cancer Center in Philadelphia. Dr. Sims and his wife have three grown sons and reside in the Seattle area. He has also served on the board of Project Access Northwest, a nonprofit that helps coordinate medical and dental care for those in need in the Pacific Northwest. Scientific Advisory Board Jeffrey L. Cummings, M.D., Sc … lude the American Association of Geriatric Psychiatry’s Distinguished Scientist Award, Melvin R. Goodes Prize for Excellence in Drug Development from the Alzheimer’s Drug Discovery Foundation, Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award, and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award. In 2024, he was ranked by ScholarGPS as the world’s top scholar for his lifetime contributions in the areas of de … onal Advisory Council on Aging (NIA Council). He is a recipient of the Potamkin Prize for his pioneering contributions to the study of preclinical AD and the accelerated evaluation of AD prevention therapies. Lon S. Schneider, MD, MS Keck School of Medicine, USC Read Bio Lon Schneider, MD, serves as Director of the USC National Institute on Aging
PharmatrophiX and Biotech Press Releases and Clinical News --> About Research & Development Neurodegenerative Diseases News & Publications Contact Who we are About PharmatrophiX About Our mission, story, and approach. Leadership Team, board, and scientific advisors Peer Reviewed Funding & Investors Our science Research & Development Research & Development Our science and development philosophy. Pipeline Programs and indications across our development stages. News & Publications External coverage and awards following PharmatrophiX, LM11A-31, and the emerging science of p75N … ’s research Sep. 16, 2015 Dr. Frank Longo wins inaugural Melvin R. Goodes Prize ADDF recognized Longo’s pioneering Alzheimer’s drug discovery work. A clinical-stage biopharmaceutical company developing therapies for neurodegenerative disease. Company About Contact Science Research Diseases Resources News & Publications Follow © 2026 PharmatrophiX, Inc. All rights reserved. Terms Privacy TOP
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
RePORT ⟩ RePORTER We're sorry but RePORTER doesn't work properly without JavaScript enabled. Please enable it to continue.
Clinical Stage Small Molecule Therapeutics Development Pipeline --> About Research & Development Neurodegenerative Diseases News & Publications Contact Who we are About PharmatrophiX About Our mission, story, and approach. Leadership Team, board, and scientific advisors Peer Reviewed Funding & Investors Our science Research & Development Research & Development Our science and development philosophy. Pipeline Programs and indications across our development stages. Our Pipeline Built on decades of foundational neuroscience research in neurotrophin receptor modulation, our pi
10-K 1 sava-20181231x10k.htm 10-K 20181231 10K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________  Form 10-K _______________   (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 or  ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 000-29959  Cassava Sciences, &n … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐ . Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K … and infrastructure;  · the sufficiency of our current resources to fund our operations over the next 12 months; and  · assumptions and estimates used for our disclosures regarding stock-based compensation. 3 Such forward-looking statements and our business are subject to numerous risks and uncertainties that you should consider before investing in our C ompany. These risks are described more fully in the section titled “Ri … blications in prestigious academic journals and multiple peer-reviewed research grant awards from the National Institutes of Health (“NIH”), the primary agency of the U.S. government for biomedical research.  In 2018, we initiated a Phase II clinical program in patients with Alzheimer’s disease using PTI-125. Our Phase II clinical program with PTI-125 is substantially funded by research grant awards from the NIH. PTI-12 … g a blood test. This clinical-stage program is substantially funded by research grant awards from the NIH. PTI-125Dx was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. We own exclusive, worldwide rights to PTI-125Dx, wi
PHARMATROPHIX INC Top 13F Holdings We give you the access and tools to invest like a Wall Street money manager – at a Main Street price. 0 Key Features Backtester Combined Holdings Excel Add-in 13F Fund Performance Evaluator Developer API 13F Stock Screener 13F Heat Map About Us Getting Started How WhaleWisdom Can Help FAQ About WhaleWisdom Contact Us Premium Subscriptions News and Articles TOU Disclaimer Privacy Policy Trademarks LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION All text and design is copyright © 2026 WhaleWisdom.com. All rights reserved.
Neurodegenerative Disease Therapies | PharmatrophiX --> About Research & Development Neurodegenerative Diseases News & Publications Contact Who we are About PharmatrophiX About Our mission, story, and approach. Leadership Team, board, and scientific advisors Peer Reviewed Funding & Investors Our science Research & Development Research & Development Our science and development philosophy. Pipeline Programs and indications across our development stages. Clinical-Stage Biopharmaceutical Promoting Resilience in Neurodegenerative Diseases Novel small-molecule therapies targetin
PSP Day: Advancing Treatment with PharmatrophiX's LM11A-31 | David Setboun, Pharm.D., MBA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo … #rarediseases #FDA #biospace https://hubs.li/Q04j4sL80 FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug biospace.com 29 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Kexing Biopharm Co.,Ltd. 4,293 followers 1w Report this post Kexingbiopharm's innovative drug "GB19 Injection" for the treatment of lupus erythematosus has completed the enrollment and administration of the first participant in its Phase
%PDF-1.7 %���� 262 0 obj > endobj xref 262 41 0000000016 00000 n 0000002004 00000 n 0000002311 00000 n 0000002394 00000 n 0000002468 00000 n 0000002547 00000 n 0000002579 00000 n 0000002679 00000 n 0000002706 00000 n 0000002851 00000 n 0000003364 00000 n 0000003594 00000 n 0000003631 00000 n 0000004023 00000 n 0000004137 00000 n 0000005762 00000 n 0000007588 00000 n 0000009062 00000 n 0000010772 00000 n 0000012675 00000 n 0000014389 00000 n 0000015187 00000 n 0000016033 00000 n 0000016441 00000 n 0000016688 00000 n 0000017581 00000 n 0000018372 00000 n 0000019183 00000 n 0000020035 00000 n 000 … ��~������k�l�xe3;��z� �G ml���;b��xI��� endstream endobj 296 0 obj >stream application/postscript _2017 AR Concepts_2.2.17 test 2 Jessica 2018-03-21T18:20:28-04:00 2018-03-21T18:20:28-04:00 2018-03-21T18:20:27-04:00 Adobe Illustrator CC 22.0 (Macintosh) xmp.iid:e860dc73-810a-4bd3-8e88-ad90f9a8edaf xmp.did:e860dc73-810a-4bd3-8e88-ad90f9a8edaf uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:a0b39acc-c959-9146-bef1-55566dce6ed4 xmp.did:dc7db0ef-7a56-4a43-adbd-48f9e5bc2 … 0 Adobe PDF library 15.00 endstream endobj 297 0 obj > endobj 298 0 obj >stream application/postscript ADDF_Logo_Primary-NEW Jessica Levine 2017-08-11T11:57:05-04:00 2017-08-11T11:57:05-04:00 2017-08-11T11:57:05-04:00 Adobe Illustrator CC 2017 (Macintosh) xmp.iid:f6aa75f2-a57b-4f9f-aeed-8f4ad944b0ca xmp.did:f6aa75f2-a57b-4f9f-aeed-8f4ad944b0ca uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:4f0e658a-0ac5-4b04-9692-6c58504d3270 xmp.did:4f0e658a-0ac5-4b04-9692-6c58504d3 … 692-6c58504d3270 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf converted from application/pdf to <unknown> saved xmp.iid:D27F11740720681191099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator CS4 / converted from application/pdf to <unknown> converted from application/pdf to <unknown> saved xmp.iid:F97F1174072068118D4ED246B3ADB1C6 2008-05-15T16:23:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:FA7F1174072068118D4ED246B3ADB1C6 2008-05-15T17:10:45-07:0 … DDFD38D0CF24DD 2008-05-16T10:35:43-07:00 Adobe Illustrator CS4 / converted from application/pdf to <unknown> saved xmp.iid:F97F117407206811BDDDFD38D0CF24DD 2008-05-16T10:40:59-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to <unknown> saved xmp.iid:FA7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:26:55-0
p75 ligands(PharmatrophiX) - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 16 Jun 2026 p75 ligands(PharmatrophiX) Last update 16 Jun 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms - Target APP Action inhibitors Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) Therapeutic Areas Nervous System Diseases Active Indication - Inactive Indication Alzheimer Disease Originator Organization Pha
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
SEC FORM D The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001. FORM D Notice of Exempt Offering of Securities OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00 1. Issuer's Identity CIK (Filer ID Number) Previ … ces Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy Health Care Biotechnology Health Insurance Hospitals & Physicians X Pharmaceuticals Other Health Care Manufacturing Real Estate … ot Applicable 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 505 X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(4) Section 3(c)(12) Section 3(c)(5) Section 3(c)(13) Section 3(c)(6) Section 3(c … more than one year? Yes X No 9. Type(s) of Securities Offered (select all that apply) X Equity Pooled Investment Fund Interests Debt Tenant-in-Common Securities Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) 10. Business Combination Transaction Is this offering being made in connection with a business combination transaction, su … tate/Province/Country ZIP/Postal Code State(s) of Solicitation (select all that apply) Check “All States” or check individual States All States Foreign/non-US 13. Offering and Sales Amounts Total Offering Amount $ 250,000 USD or Indefinite Total Amount Sold $ 250,000 USD Total Remaining to be Sold $ 0 USD or Indefinite Clarification of Response (
PharmatrophiX Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners